Hyal Pharmaceutical Corp. (NASDAQ/NMS:HYALP) ofMississauga, Ontario, has received approval under a Canadianinvestigational new drug application to begin a Phase IIIclinical trial on its topical analgesia, AT2101, for relief of painassociated with acute osteoarthritis of the knee.
The Phase III trial at the University Hospital in London,Ontario, will compare the pain relief capability of thishyaluronic acid-based gel containing a non-steroidal anti-inflammatory drug with a placebo.
The Canadian trial follows a successful Phase III clinical trialconducted by K. Chlud in Austria. Chlud, president of theEuropean League Against Rheumatism, conducted a double-blind controlled comparative trial at the Kaiser Franz JosefHospital in Vienna. The results of this trial noted significantlevels of efficacy in 60 rheumatoid and osteoarthritic patients.
(c) 1997 American Health Consultants. All rights reserved.